COMP <GO>
NBIX vs UNH // REVENUE GROWTH (YOY)
Neurocrine Biosciences Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NBIX 8
— UNH 6
▲ REVENUE GROWTH (YOY) LEADER: NBIX
LAST: $145.35 (-0.51%) • MKT CAP: $14.77B
revenue-growth
21.40%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBIX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.31% | +7.69 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.70% | 12.38% | +3.32 | NBIX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.8x | 15.3x | +7.53 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.03% | 6.25% | -1.22 | UNH | /fcf-yield <GO> |
| Operating Margin | 21.60% | 5.32% | +16.28 | NBIX | /operating-margins <GO> |
| Net Profit Margin | 16.70% | 3.53% | +13.17 | NBIX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 21.40% | 3.33% | +18.07 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.13 | 3.09 | +5.04 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 55.1 | -2.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.33 | +0.80 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 17.7x | +8.36 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.77B | $359.43B | -$344.66B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBIX REV | UNH REV | NBIX GROSS % | UNH GROSS % | NBIX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $447.57B | 98.2% | 88.7% | $748.7M | $16.07B |
| FY 2024 | $2.36B | $400.28B | 98.6% | 88.3% | $557.2M | $20.70B |
| FY 2023 | $1.89B | $371.62B | — | 89.6% | $305.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
UNH // BETA 0.33